FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma
The FDA has accepted a supplemental biologics application for ILUMYA (tildrakizumab) from Sun Pharma.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Immunology / IL-23
Company: Sun Pharma
Asset: ILUMYA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Sun Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for ILUMYA positions Sun Pharma to strengthen its market presence in the IL-23 inhibitor segment. This development may trigger competitive responses from major players like AbbVie and Merck, necessitating strategic adjustments.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review outcomes and any subsequent competitive reactions.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.